Cargando…
A Role for Fragment-Based Drug Design in Developing Novel Lead Compounds for Central Nervous System Targets
Hundreds of millions of U.S. dollars are invested in the research and development of a single drug. Lead compound development is an area ripe for new design strategies. Therapeutic lead candidates have been traditionally found using high-throughput in vitro pharmacological screening, a costly method...
Autores principales: | Wasko, Michael J., Pellegrene, Kendy A., Madura, Jeffry D., Surratt, Christopher K. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4566055/ https://www.ncbi.nlm.nih.gov/pubmed/26441817 http://dx.doi.org/10.3389/fneur.2015.00197 |
Ejemplares similares
-
Editorial: In silico Modeling of Brain Receptors for Antidepressants, Psychostimulants, and Other CNS-Active Drugs
por: Surratt, Christopher K., et al.
Publicado: (2016) -
Discovery of Novel-Scaffold Monoamine Transporter
Ligands via in Silico Screening with the S1 Pocket of the Serotonin
Transporter
por: Nolan, Tammy L., et al.
Publicado: (2014) -
Target Molecules of STIM Proteins in the Central Nervous System
por: Serwach, Karolina, et al.
Publicado: (2020) -
Drugs acting on central nervous system (CNS) targets as leads for non-CNS targets
por: Kharkar, Prashant S.
Publicado: (2014) -
Editorial: Central nervous system acting drugs-molecular mechanisms of neuroprotection and neurodegeneration
por: El Sayed, Nesrine S., et al.
Publicado: (2022)